News

Published on 7 Jun 2023 on Benzinga via Yahoo Finance

Baudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery Patients

Article preview image

Baudax Bio Inc (NASDAQ: BXRX) announced additional results from its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Additional electromyography (EMG) analyses of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.

Read the rest of the article
NASDAQ.BXRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock Now

The price trend for Baudax Bio, Inc. (BXRX) has been bearish lately and the stock has lost 9.1% o...

Zacks via Yahoo Finance 18 Sep 2023
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune

Baudax Bio BXRX acquired TeraImmune, a privately held company that’s focused on the discovery and...

Zacks via Yahoo Finance 3 Jul 2023
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data

Baudax Bio, Inc. BXRX announced additional positive data from its phase II study of BX1000, which...

Zacks via Yahoo Finance 8 Jun 2023
Baudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery Patients

Baudax Bio Inc (NASDAQ: BXRX) announced additional results from its Phase 2 trial of BX1000 for n...

Benzinga via Yahoo Finance 7 Jun 2023
Lab Notes: Jefferson Institute for Bioprocessing undergoing multimillion-dollar expansion

This week's life sciences industry news includes items on a bioprocessing institute's expansion...

The Business Journals 28 Apr 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.57% By Investing.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.57%

Investing.com 27 Apr 2023
Baudax Bio Prices 3.48M Share Offerings at $1.15/sh By Investing.com

Baudax Bio, Inc. (BXRX), a pharmaceutical company focused on innovative products for hospital and...

Investing.com 27 Apr 2023
Baudax Bio Prices 3.48M Share Offerings at $1.15/sh By Investing.com

Baudax Bio, Inc. (BXRX), a pharmaceutical company focused on innovative products for hospital and...

Investing.com 26 Apr 2023
Baudax Bio's Nerve Blockade Aces Mid-Stage Study In Surgery Patients

Baudax Bio Inc (NASDAQ: BXRX) announced top-line results from its Phase 2 clinical trial of BX100...

Benzinga via Yahoo Finance 25 Apr 2023
Why Baudax Bio Shares Are Trading Higher Today

Baudax Bio Inc (NASDAQ: BXRX) announced results from the second preplanned interim analysis of it...

Benzinga via Yahoo Finance 27 Mar 2023

Copyright Statfolio @ 2025

Social Accounts